

WMS 2026 Summary Programme

(Subject to change)

Version: 07/10/26

Monday 28 September 2026

08:30-19:00

Pre-Congress Teaching Course (separate registration required)

📍 Orchid Ballroom 3, ANA Crowne Plaza



Tuesday 29 September 2026

08:30-11:30

Pre-Congress Teaching Course (separate registration required)

📍 Orchid Ballroom 3 and Acacia, ANA Crowne Plaza



10:00-15:00

WMS Executive Board Meeting (by invitation only) 📍 ANA Crowne Plaza

13:00-17:00

Registration and poster set up 📍 International Congress Center Hiroshima (ICCH)

Poster set up is only available for posters being shown in the Conference Management Room

14:00-15:00

Early to mid-career peer networking session (separate registration required) 📍 Cosmos ICCH



15:00-16:00

Regional networking (separate registration required) 📍 Ran ICCH



16:00-17:00

Industry Symposium 1 📍 Himawari Hall ICCH

Industry Symposium 2 📍 Phoenix Hall ICCH

17:00-18:00

Registration for Opening Ceremony and Networking Reception 📍 Level 3 Foyer, ANA Crowne Plaza

18:00-18:45

Opening Ceremony (separate registration required) 📍 Orchid Ballroom, ANA Crowne Plaza



18:45-21:00

Networking Reception (separate registration required)

📍 Orchid Ballroom, Acacia and Cattleya rooms, ANA Crowne Plaza



Wednesday 30 September 2026

📍 All subsequent sessions will take place at ICCH

(except NMD Editorial Board Meeting and Industry Symposia 6 and 7 at ANA Crowne Plaza)

07:15-19:00

Congress desk open

07:45-08:45

Industry Symposium 3 📍 Himawari Hall

Industry Symposium 4 📍 Phoenix Hall

09:00-09:30

Congress Welcome - Message from the President 📍 Phoenix Hall

09:30-11:00

Topic 1: Myotonic disorders (DM1), basic biology and treatment options 📍 Phoenix Hall

Moderators: Vishnu Venugopalan Yamuna, All India Institute of Medical Sciences, India and Nicol Voermans, Radboud University Medical Centre, Netherlands

09:30-10:00

01INV Unstable DNA in myotonic dystrophy type 1: dynamics, consequences and therapeutic opportunities

Darren Monckton, University of Glasgow, United Kingdom

10:00-10:30

02INV Brain and heart involvement in myotonic dystrophies: causes and consequences

Cornelia Kornblum, University Hospital Bonn, Germany

10:30-10:45

01O Different cognitive profiles and their brain MRI correlates in adult myotonic dystrophy type 1

Jean-Baptiste Davion, Hôpital Swynghedauw Chu Lille, France

	10:45-11:00	02O Methylation of CCG variant repeats is associated with heterogeneous CpG methylation flanking DMPK expansion in patients with myotonic dystrophy type 1 <i>Jovan Pesovic, University of Belgrade, Serbia</i>		
11:00-14:00	Poster set up 📍 <i>Himawari Hall</i>			
11:00-11:30	Morning refreshments, exhibition and poster viewing			
11:00-11:30	Myology Café Meet the committee 📍 <i>Sakura room</i>			
11:30-13:30	Topic 1: Myotonic disorders and OPDM 📍 <i>Phoenix Hall</i> <i>Moderators: Hacer Durmus, Istanbul University, Istanbul Faculty of Medicine Turkey and Takashi Kurashige, NHO Kure Medical Center and Chugoku Cancer Center, Japan</i>			
	11:30 -12:00	03INV Advances in translational therapeutics for DM1 <i>Masayuki Nakamori, Yamaguchi University, Japan</i>		
	12:00-12:30	04INV Central nucleation in myotonic dystrophy: beyond classical degeneration-regeneration <i>Vanessa Todorow, University College London, United Kingdom</i>		
	12:30-12:45	03O Long-term functional improvement with zeleciment basivarsen in the phase 1/2 ACHIEVE trial <i>Karlien Mul, Radboud University Medical Center, Netherlands</i>		
	12:45-13:00	04O ELIXIR, a synthetic peptide modulator of sodium channel inactivation, suppresses myotonia in a mouse model of hyperkalemic periodic paralysis <i>Steve Cannon, David Geffen School of Medicine at UCLA, United States of America</i>		
	13:00-13:15	05O Tandem repeat pathogenicity signature unlocks oculopharyngeal distal myopathy discoveries <i>Stephan Zuchner, University of Miami, United States of America</i>		
	13:15-13:30	06O Gene-specific repeat architecture and methylation shape clinical variability in oculopharyngodistal myopathy <i>Nobuyuki Eura, Nara Medical University, Japan</i>		
13:30-14:30	Lunch, exhibition and poster viewing			
13:45-14:30	NMD Editorial Board Meeting (by invitation only) 📍 <i>Acacia Room, ANA Crowne Plaza</i>			
14:30-15:30	Poster session 1 1.009eP-1.020eP, 1.001P- 1.010P: LGMD - Clinical care and case reports 1.021eP- 1.025eP, 1.011P- 1.014P: LGMD - Imaging and outcome measures 1.026eP- 1.029eP, 1.015P-1.016P: LGMD - Pathophysiology of NMDs 1.030eP- 1.031eP, 1.017P: LGMD – Treatments 1.032eP- 1.036eP, 1.018P- 1.026P: Multiorgan syndromes 1.037eP- 1.054eP, 1.027P- 1.033P: Neurogenic Disorders - Clinical care and case reports 1.055eP- 1.058eP, 1.034P, 1.036P: Neurogenic disorders - Imaging and outcome measures 1.037P-1.038P: Neurogenic disorders – Physiopathology 1.039P-1.043P: Neurogenic Disorders – Treatments 1.059eP, 1.045P-1.050P: Novel molecular genetic approaches for NMD 1.060eP- 1.088eP, 1.051P-1.073P: SMA - Clinical care and case reports 1.089eP-1.097eP, 1.074P- 1.082P: SMA - Imaging and outcome measures 1.098eP- 1.099eP, 1.083P- 1.087P: SMA – Physiopathology 1.100eP- 1.104eP, 1.088P-1.090P: SMA – Treatments 1.091LBP, 1.093LBP - 1.107LBP: Late breaking			
15:30-16:00	Short Oral Presentations 1 📍 <i>Ran</i> Congenital myopathies, mechanisms and therapies SP01-SP05 <i>Moderator: Yukari Endo, Juntendo University, Japan</i>	Short Oral Presentations 2 📍 <i>Cosmos 1</i> Toxic and inflammatory myopathies SP06-SP09 <i>Moderator: Olivier Benveniste, Sorbonne Université, France</i>	Short Oral Presentations 3 📍 <i>Cosmos 2</i> DMD treatments SP10-SP15 <i>Moderator: Aoki Yoshitsugu, National Center for Neurology and Psychiatry, Japan</i>	

16:15-17:00	Congress Debate 📍 Phoenix Hall Can the neuromuscular field discontinue the use of animals in research? <i>Moderators: Francesco Saverio Tedesco, University College London, GOSH and the Francis Crick Institute, United Kingdom</i> 13INV Hidetoshi Sakurai, Center for iPS, Japan 14INV Emma Rybalka, Victoria University, Australia <i>The WMS Congress Debate has quickly become one of the most popular elements of the entire scientific programme. This year, the debate will tackle a critical and timely question that strikes at the very heart of translational science: Can the neuromuscular field discontinue the use of animals in research?</i> <i>For decades, animal models have served as the cornerstone of drug discovery and disease modelling. However, persistent translational gaps, where promising preclinical breakthroughs fail in human clinical trials, coupled with major regulatory shifts such as the FDA Modernization Act 2.0 and rapid advances in human iPSC technologies, 3D bioengineered tissues, and Microphysiological Systems (MPS), have brought us to an historic crossroads.</i> <i>Should we completely transition away from animal models in favour of human-centric, non-animal methodologies to accelerate effective therapies for patients? Or do animal models remain an irreplaceable necessity for capturing complex, systemic physiology that can vary across the lifespan, that cannot yet be fully replicated on a chip? Is a future without animal testing a logical, scientific evolution... or an unrealistic ideal?</i> <i>The debate team includes world-renowned experts in muscle biology and translational research: Hidetoshi Sakurai (Japan), who will argue in favour of discontinuing the use of animals in research, and Emma Rybalka (Australia), who will be arguing against, with expert moderation by Francesco Saverio Tedesco (UK).</i> <i>In an effort to demonstrate differing viewpoints, as well as to educate and entertain, Hidetoshi and Emma will intentionally present extreme positions that may not convey their actual and nuanced perspectives on this important issue.</i> <i>To round off this interactive discussion, the debaters will offer their genuine reflections on the future of disease modelling and present their insights regarding the real-world complexities of translational research.</i> <i>We encourage members of the audience to participate in the live polling and discussion. Please join us for what we are sure will be another Congress highlight!</i>		
17:15-18:15	Poster session 2 2.001eP-2.002eP, 2.001P-2.003P: Becker muscular dystrophy 2.003eP-2.009eP, 2.004P-2.012P: CMD - Clinical care and case reports 2.013P-2.016P: CMD – Physiopathology 2.010eP-2.028eP, 2.85eP, 2.017P-2.039P, 2.001VP: DMD - clinical care and case reports 2.029eP-2.031eP, 2.040P-2.052P, 2.002VP: DMD - imaging and outcome measures 2.033eP-2.045eP, 2.047eP-2.065eP, 2.067eP, 2.053P-2.088P, 2.129P: DMD – treatments 2.068eP-2.072eP, 2.089P-2.105P, 2.003VP: Dystrophinopathies 2.073eP-2.084eP, 2.106P-2.128P: Pathophysiology of NMDs 2.086eP-2.090eP: Environmental Sustainability		
18:15-18:45	Short Oral Presentations 4 📍 Ran Congenital myopathies SP16-SP20 <i>Moderator: Yuko Shimizu-Motohashi, National Center of Neurology and Psychiatry, Japan</i>	Short Oral Presentations 5 📍 Cosmos 1 Myotonic dystrophy mechanisms SP21-SP24 <i>Moderator: Guillaume Bassez, Pitié Salpêtrière Hospital, France</i>	Short Oral Presentations 6 📍 Cosmos 2 Modeling disease mechanisms SP25-SP27 <i>Moderator: Helge Amthor, Versailles University, France</i>
19:00-20:00	Industry Symposium 5 📍 Phoenix Hall (ICCH)	Industry Symposium 6 📍 Orchid Higashi, ANA Crowne Plaza	Industry Symposium 7 📍 Orchid Nishi, ANA Crowne Plaza

Thursday 1 October 2026

📍 All sessions will take place at ICCH

07:30-16:00	Congress desk open
08:00-09:00	Early to mid-career peer breakfast session 📍 <i>Myology Café, Sakura Room</i>
09:00-10:30	Topic 2: Drug-induced myopathies 📍 <i>Phoenix Hall</i> <i>Moderators: Yves Allenbach, Sorbonne Université, France and Wen-Chen Liang, Kaohsiung Medical University Hospital, Taiwan</i> 09:00-09:30 05INV Immune-mediated necrotizing myopathy vs. Drug-induced myopathy: the central role of statins and HMGCR-autoantibodies <i>Lisa Christopher-Stine, Johns Hopkins University School of Medicine, United States of America</i> 09:30-10:00 06INV MADD related lipid storage myopathy: from genetic to toxic <i>Chuanzhu Yan, Shandong University, China</i> 10:00-10:15 07O An Interdisciplinary Evaluation of the Impact of GLP-1 Receptor Agonists in individuals with Duchenne Muscular Dystrophy <i>Meilan Rutter, Cincinnati Children's Hospital Medical Center, United States of America</i> 10:15-10:30 08O Motor peripheral neuropathy in patients with nitrous oxide abuse involves homocysteine toxicity through the unfolded protein response <i>Arnaud Jacquier, Centre National de la Recherche Scientifique, France</i>
10:30-11:00	Morning refreshments, exhibition and poster viewing
10:30-11:00	Myology Café Meet the committee 📍 <i>Sakura room</i>
11:00-13:00	Topic 2: Drug-induced and infectious myopathies 📍 <i>Phoenix Hall</i> <i>Moderators: Marianela Schiava, The John Walton Muscular Dystrophy Research Centre, United Kingdom and Werner Stenzel, Charité University Hospital Berlin, Germany</i> 11:00-11:30 07INV Infectious myositis: from pyomyositis to parasitic infection <i>Jantima Tanboon, Mahidol University, Thailand</i> 11:30-12:00 08INV Immune checkpoint inhibitors induced myotoxicities - from pathophysiology to personalized management <i>Joe-Elie Salem, Sorbonne University, France</i> 12:00-12:15 09O Drug-induced myopathies: a pharmacovigilance-based study of the spectrum of drug toxicity, with a focus on anticancer agents <i>Julian Sanchez-Dal Cin, Assistance Publique Hôpitaux De Paris, France</i> 12:15-12:30 10O Defining the Histopathologic Spectrum of ICI-Related Myositis: Toward Validation of a Standardized Diagnostic Score <i>Beatrice Labella, Pitié-Salpêtrière Hospital, France</i> 12:30-12:45 11O A comparative study of sporadic and immune checkpoint inhibitor-related forms of myasthenia gravis-myositis (MG-IM) overlap syndrome <i>Antonio Lauletta, Sapienza University of Rome, Italy</i> 12:45-13:00 Q&A Session
13:00-14:00	Lunch, exhibition and poster viewing
14:00-16:00	Interesting case discussions 📍 <i>Phoenix Hall</i> <i>Moderators: Jorge Bevilacqua, Hospital Clínico Universidad de Chile, Chile, Emna Farhat, The Muscle Lab, Tunisia and Wenhua Zhu, Huashan Hospital, Fudan University, China</i> Case 1: More Than One Disease: Dual SCN4A-Related Congenital Myopathy and Riboflavin-Responsive COASY Myopathy <i>Erin Nuro, Western University, Canada</i>

Case 2: A teenage girl with proximal upper extremities weakness and muscle atrophy

Jean Mah, University of Calgary, Canada

Case 3: An Infectious Neuropathy Masquerading as MADSAM: The Diagnostic Value of Nerve Biopsy

Hung Dang, University Medical Center Ho Chi Minh City, Vietnam

Case 4: When muscle weakness meets unusual cutaneous lesions

Gianmarco Severa, Inserm U955 Imrb, France

Case 5: Neuromuscular endplate pathology in recessive desminopathies

Hacer Durmus, Istanbul University, Istanbul Faculty of Medicine Turkey

Case 6: IgM-k Monoclonal Gammopathy–Associated Myopathy Secondary to Waldenström Macroglobulinemia

Xiaoqing Lyu, Qilu Hospital of Shandong University, China

Case 7: ACTA1 c.716A>G (p.Glu239Gly): distal myopathy with actinopathy features

Enzo Pellacani, Centro Universitário Fmabc, Brazil

Case 8: Autophagic vacuolar myopathy with progressive bulbar failure in three sisters: an unsolved family case

Giulio Gadaleta, University of Turin, Italy

16:00-18:30

Poster viewing/group activity (separate registration required)

Please note there is no group activity networking reception this year.



Friday 2 October 2026

📍 All sessions will take place at ICCH

08:00-17:15	Congress desk open
08:30-10:15	Topic 3: Trust, transparency and therapeutic understanding 📍 Phoenix Hall <i>Moderators: Tamara Dangouloff, University of Liege, Belgium and Teerin Liewluck, Mayo Clinic Rochester, United States of America</i> 08:30-08:45 12O Raising reasonable expectation : A collective responsibility <i>Laurent Servais, President, WMS</i> 08:45-09:15 09INV Hope You Can Trust: Transparency as the Foundation of Breakthroughs in Treating Neuromuscular Disorders <i>Emily Reuben, Duchenne UK, United Kingdom</i> 09:15-09:45 10INV From trials to treatment: Risk-benefit misestimation across the therapeutic lifecycle <i>Kathryn Wagner, Johns Hopkins School of Medicine, United States</i> 09:45-10:15 11INV Data, disclosure, and the meaning of benefit in NMD trials <i>Maryam Oskoui, Centre Hospitalier Universitaire Sainte-Justine, Canada</i>
10:15-10:45	Morning refreshments, exhibition and poster viewing
10:15-10:45	Myology Café Meet the committee 📍 Sakura room
10:45-12:30	Topic 3: Advancements in neuromuscular diseases 📍 Phoenix Hall <i>Moderators: Duygu Selcen, Mayo Clinic, United States of America and Conrad Weihl, Washington University Medical University, United States of America</i> 10:45-11:00 13O Myo-guide: a one-stop cloud platform for AI-based muscle MRI segmentation, quantification, analysis and sharing <i>José Verdú Díaz, John Walton Muscular Dystrophy Research Centre, United Kingdom</i> 11:00-11:15 14O Design of skeletal muscle-specific promoters active in slow and fast muscle fiber types for rAAV-driven treatment of LGMDR1 <i>Ruby Goldstein De Salazar, UCLA, United States of America</i> 11:15-11:30 15O VMA21 deficiency leads to autophagic dysregulation, altered vesicle trafficking, and complement deposition in X-linked myopathy with excessive autophagy <i>Michio Inoue, Washington University in St. Louis, United States of America</i> 11:30-11:45 16O Bi-allelic variants in DMXL1 cause a novel autophagic vacuolar myopathy <i>Chiara Folland, Australia</i> 11:45-12:30 Q&A session
12:30-14:00	Lunch, exhibition and poster viewing
12:45-13:45	WMS General Assembly 📍 Phoenix Hall / poster viewing for non-members
14:00-14:30	Sponsor meeting 📍 Ran (by invitation only)
14:15-15:15	Poster session 3 3.001eP-3.005eP, 3.001P-3.012P: Distal myopathies and OPMD 3.006eP-3.015eP, 3.013P-3.020P: Drug-induced and infectious myopathies 3.016eP-3.024eP, 3.021P-3.028P: FSHD - Clinical care and case reports 3.025eP-3.029eP, 3.029P-3.038P: FSHD - Imaging and outcome measures 3.030eP, 3.039P-3.047P: FSHD - Pathophysiology of NMDs 3.031eP, 3.048P-3.049P: FSHD – Treatments 3.032eP-3.036eP, 3.050P-3.057P: Glycogenoses 3.037eP-3.066eP, 3.058P-3.098P: Idiopathic inflammatory myopathies

	3.067eP-3.068eP: Lipid storage myopathies 3.069eP-3.075eP, 3.099P-3.106P: Mitochondrial disorders 3.076eP-3.078eP, 3.107P-3.116P: Vacuolar myopathies 3.079LBeP - 3.089LBeP: Late breaking		
15:15-15:45	Short Oral Presentations 7 📍 <i>Ran</i> Congenital muscle diseases SP28-SP31 <i>Moderator: Keiko Ishigaki, Tokyo Women's Medical University, Japan</i>	Short Oral Presentations 8 📍 <i>Cosmos 1</i> Myotonic dystrophy therapies SP32-SP35 <i>Moderator: Benedikt Schoser, Friedrich-baur-institut Lmu München, Germany</i>	Short Oral Presentations 9 📍 <i>Cosmos 2</i> Clinical care SP36-SP39 <i>Moderator: Kristin Ørstavik, Oslo University Hospital, Norway</i>
15:45-16:45	Poster session 4 4.001eP-4.010eP, 4.001P-4.007P: CMyo - Clinical care and case reports 4.011eP-4.014eP, 4.008P-4.020P: CMyo - Clinical physiopathology 4.015eP-4.017eP, 4.021P-4.022P: Congenital myasthenic syndrome 4.018eP-4.027eP, 4.023P-4.029P: Muscle imaging 4.028eP-4.037eP, 4.030P-4.033P: Myasthenia gravis 4.039eP-4.059eP, 4.034P-4.070P: Myotonic disorders and Periodic Paralysis 4.060eP-4.088eP-4.071P-4.092P: Registries, networks and care		
16:45-17:15	Short Oral Presentations 10 📍 <i>Ran</i> Neurogenic disorders SP40-SP43 <i>Moderator: Heike Kölbels, Universitätsmedizin Essen, Germany</i>	Short Oral Presentations 11 📍 <i>Cosmos 1</i> LGMD SP44-SP48 <i>Moderator: Motoi Kanagawa, Ehime University, Japan</i>	Short Oral Presentations 12 Novel approaches in NMD 📍 <i>Cosmos 2</i> SP49-SP53 <i>Moderator: Jaakko Sarparanta, Folkhälsan Research Center, Finland</i>
18:30-23:00	Networking Dinner 📍 <i>Grand Prince Hotel Hiroshima (separate registration required)</i>		



📍 All sessions will take place at ICCH

07:15-14:30	Congress desk open
07:30-09:00	Clinical trial updates 📍 Phoenix Hall <i>Moderators: Liesbeth De Waele, University Hospitals Leuven, Belgium and Hirofumi Komaki, National Center of Neurology and Psychiatry, Japan</i> 07:30-07:45 170 07:45-08:00 180 08:00-08:15 190 08:15-08:30 200 08:30-08:45 210 08:45-09:00 220
09:00-09:15	Comfort break
09:15-09:45	Victor Dubowitz Lecture 📍 Phoenix Hall <i>Moderators: Jenni Laitila, Folkhälsan Research Center, Finland and Laurent Servais, University of Oxford, United Kingdom</i> 15INV My journey around the nuclear envelope <i>Gisèle Bonne, Institut de Myologie, France</i>
09:45-11:15	Poster highlights 📍 Phoenix Hall <i>Moderators: Marco Savarese, Samfundet Folkhälsan, Finland and Kazuma Sugie, Nara Medical University, Japan</i> 09:45-10:00 230: Mitochondrial dysfunction in myotonic dystrophy type 1 <i>Najoua El Boujnouni, Radboud University Medical Center, Netherlands</i> 10:00-10:15 240: Serum myostatin as a diagnostic biomarker in neuromuscular disorders: evaluation in a large cohort and correlation with clinical surrogates of disease severity <i>Alexander Mensch, University Medicine Halle, Germany</i> 10:15-10:30 250: Spatial dynamics between resident immune cells involve an IFNγ and IL15 axis in immune checkpoint blockade-induced muscle toxicity <i>Julian Sanchez-Dal Cin, Assistance Publique Hôpitaux De Paris, France</i> 10:30-10:45 260: Biallelic MCUR1 nonsense mutation associated with vacuolar myopathy and altered mitochondrial calcium signalling <i>Anna-Maria Haschke, Charité - Universitätsmedizin Berlin, Germany</i> 10:45-11:00 270: No evidence of the presence of dystrophin protein in rodent muscle stem cells <i>Helge Amthor, Versailles University, France</i> 11:00-11:15 280: Predicting the 95th centile stride velocity (SV95C) at 6-, 12-, 18-, and 24-months in steroid-treated boys with Duchenne muscular dystrophy <i>Georgia Stimpson, University of Oxford, United Kingdom</i>
11:15-11:45	Morning refreshments, exhibition and poster viewing
11:45-13:15	Late breaking news 📍 Phoenix Hall <i>Moderators: Alan Beggs, Boston Children's Hospital/Harvard Medical School, United States of America and Anna Cho, Seoul National University Bundang Hospital, South Korea</i> 11:45-11:57 01LBO Restoration of brain dystrophin with neuronal targeted AAV Microdystrophin or Dp140 in mdx52 mice of Duchenne muscular dystrophy <i>Konstantina Tetorou^{1,2}, Eleanor Davis, Sophia Tan, Vincent Lau, Simon Waddington, Joanne Ng, Francesco Muntoni</i> ¹Genetic Therapy Accelerator Centre, UCL Queen Square Institute of Neurology, London WC1N 3BG, London, United Kingdom, ²Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, and NIHR Biomedical Research Centre, London WC1N 3JHL, London, United Kingdom,

11:57-12:09	02LBO First-in-human evidence of RNA activation-mediated sarcolemmal utrophin upregulation in Duchenne muscular dystrophy <u>Yi Dai</u>¹, Han-Hui Fu, Shawn Zhang, Wei-Hsiang Lin, Moorim Kang, Long-Cheng Li ¹Department of Neurology, Peking Union Medical College Hospital, Beijing, China
12:09-12:21	03LBO LAMA2-related Muscular Dystrophy: How Nonsense-Associated Alternative Splicing Offers Cellular Protection <u>Louise Benarroch</u>¹, Lauren Struble, Corine Gartioux, Teresinha Evangelista, Tanya Stojkovic, Valérie Allamand ¹Centre de Recherche en Myologie – Umr974, Paris, France
12:21-12:33	04LBO Biallelic truncating variants in the muscle-specific gamma isoform of MYO18A are associated with a severe congenital myopathy <u>Kathryn Yammine</u>¹, Casie Genetti, Samwael Armoush, Laura Covill, Vijay Ganesh, Anne O'Donnell-Luria, Regina Laine, Elicia Estrella, Won Lee, Claudia Castiglioni, Leonela Luce, Jordi Díaz-Manera, Volker Straub, Ana Töpf, Mari Mori, Monica Wojcik, Alan Beggs ¹The Manton Center for Orphan Disease Research, Boston Children's Hospital, Harvard Medical School, Boston, United States
12:33-12:45	05LBO CM4620 treatment prevents and reverses tubular aggregate myopathy/Stormorken syndrome (TAM/STRMK) Emma Lafabrie, Jocelyn Laporte, <u>Johann Böhm</u>¹ ¹IGBMC / University of Strasbourg, Strasbourg, France
12:45-12:57	06LBO TPC2 activation overcomes a glycogen-clearance bottleneck in late-onset Pompe disease <u>Peter Meinke</u>¹, Stefan Hintze, Eva Krois, Vilma Moisiu, Alexandra Graupner, Hanseul Oh, Giulia Ferrero, Malin Larsen, Vanessa Todorow, Karin Wieland, Marco Keller, Franz Bracher, Christian Grimm, Andreas Wieser, Christoph Haisch, Benedikt Schoser ¹Friedrich-Baur-Institute, LMU Munich, Munich, Germany
12:57-13:09	07LBO Novel biallelic HMGCS1 variants linked to a progressive immuno-metabolic necrotizing myopathy with membrane attack complex deposition <u>Edoardo Malfatti</u>^{1,2}, Alexandru Caramizaru, Iago Pinal-Fernandez, Gustaf Wigerblad, Sabrina Helmod Hait, Gina Ravenscroft, Dhanya Lakshmi Narayanan, Suma Balan, Vaishnavi Ashok Badiger, Wenjuan Liu, Stefania Dell'Orso, Deborah Stone, François-Jérôme Authier, Michael Rogers, Pascal Laforêt, Alix de Becdelièvre, Seth L Masters, Danica Novacic, Ivona Aksentijevich, HMGCS1-Related Myopathy Study Group ¹IMRB Inserm U955 Team Malfatti - UPEC, Créteil, France, ²Reference Center for Neuromuscular Disorders, APHP Henri Mondor University Hospital, Créteil, France
13:15-13:45	Prize Giving Ceremony 📍 Phoenix Hall Introduction to the WMS 2027 Congress, Helsinki, Finland, handover of the WMS flag and close of the Congress
13:45-14:30	Homeward lunch